Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Other Non-current Assets

Long-term assets not reported separately.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Other Non-current Assets · Q2 FY2026 · quarter ended Jun 2026

Other non-current assets of $2.62M in Q2 FY2026

Q2 FY2026 other non-current assets was $2.62M.

Context

  • Other non-current assets amounted to 2.0% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.62M+69.2% QoQ
Last fiscal yearDec 2025
$1.33M+238.2% YoY
Other Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+238.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-current Assets history

USD · from the balance sheet

Latest · FY2025
1.33M USD
Year-over-year change
+238.2%
1-year CAGR
+238.2%

Other Non-current Assets vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
  • Other non-current assets amounts to 2.0% of total assets for ATTO, versus a peer median of 0.6%.
ATTO Competitors
Other Non-current Assets for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALMSAlumis Inc. Common StockJun 2026$3.28M USD-14.9%+88.2%0.6%
ATTOAttovia Therapeutics, Inc.Jun 2026$2.62M USD——2.0%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€2.21M EUR——1.3%
ZURAZura Bio LimitedMar 2026$1.51M USD+116.6%-24.3%0.7%
MLTXMoonLake ImmunotherapeuticsMar 2026$1.34M USD-20.8%—0.3%
QTTBQ32 Bio Inc.Mar 2026$647K USD-40.7%—1.0%
CNTBConnect Biopharma Holdings LimitedDec 2025$646K USD+1857.6%+36.9%1.2%
ANABAnaptysBio, Inc.Mar 2026$256K USD+0.0%+0.0%0.1%
ACRSAclaris Therapeutics, Inc.Mar 2026$231K USD-92.7%—0.1%
ORKAOruka Therapeutics, Inc.Sep 2026$128K USD+24.3%+78.9%0.0%
EVMNEvommune, Inc.Mar 2026-$2.13M USD-3593.5%—0.7%
Peer median (excluding ATTO) —-14.9%+36.9%0.6%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.